An interventional study of Photobiomodulation in Parkinson Disease, Pain and Photobiomodulation, sponsored by University of Sao Paulo. Recruiting at 2 sites in Brazil. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-07-25.
Sponsored by University of Sao Paulo · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 103 studies in Parkinson Disease with a site in Brazil — 19 open to participants now, 22 under way, 1 of them phase 3. Parkinson Disease · Brazil.
Among the 103 studies in Parkinson Disease with a site in Brazil, this one is the 12th largest by planned enrollment of the 95 interventional ones that give a count, is one of 9 that started in 2023, is one of 81 with no phase, reaches primary completion later than 0 of the 21 other live ones, and was the 80th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →19 of the 103 studies in Parkinson Disease with a site in Brazil are open now. Recruiting first, the newest first:
Universidade Metodista de Piracicaba · Sites in Brazil
Ages 50–80
Hospital de Clinicas de Porto Alegre · Sites in Brazil
Ages 18+
Raphael Mendes Ritti Dias · Sites in Brazil
Ages 40+
Universidade Federal de Pernambuco · Sites in Brazil
Ages 40+
Hoffmann-La Roche · Sites in Brazil, United States, Australia and 14 more countries
Ages 50–85
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 50 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
103 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 9
First in 2002; this study’s year is marked. 9 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 82 is above the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 34 across the 95 interventional studies, 322 across the 8 observational. Of the 53 that completed or were terminated, 3 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 103 have an industry lead sponsor. The 10 most frequent:
University of Sao Paulo is the lead sponsor of 1,036 studies on the registry; 96 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
University of Sao Paulo has 7 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
9 of the studies in Parkinson Disease with a site in Brazil that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07488026Universidade Federal de PernambucoEffects of the Stimulation Site of tsMS With TMS on Functional Mobility in Individuals With Parkinson's Disease | 2026-11 |
| NCT07172698Federal University of Health Science of Porto AlegreEffects of a Multicomponent Protocol With Emphasis on Muscle Power Training on Bradykinesia in Individuals With Parkinson's Disease | 2026-12-01 |
| NCT06921122Hospital de Clinicas de Porto AlegreUse Of A Tongue Strength Training Device And Its Relationship With Speech In Patients With Parkinson's Disease | 2026-12-20 |
| NCT06815302Oregon Health and Science UniversityTURN-IT FOG: Improving Turning and Freezing of Gait in People With PD | 2026-12-31 |
| NCT07567599Federal University of Minas GeraisDeep Brain Stimulation in Parkinson's Disease: Motor and Functional Outcomes | 2027-02 |
Add all 9 to your calendar (.ics) → With an account.
Among the 103 studies in Parkinson Disease with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Parkinson's disease is a progressive and degenerative neurological movement disorder that affects thousands of people. The disease is characterized by presenting motor and non-motor symptoms, as the disease progresses, it becomes more disabling, making it impossible for the individual to perform simple tasks. A non-motor symptom increasingly reported by patients and undertreated in clinical practice is pain. During the past few decades, possible neural substrates of pain have been studied extensively, resulting in a potential network of connected brain areas that are believed to underlie pain processing and experience. There is no definitive consensus on all areas involved in such a pain network; however, pain-related regions consistently found across all studies include the thalamus, anterior cingulate cortex (ACC), posterior and anterior insula, amygdala, prefrontal cortex (PFC), secondary somatosensory cortex (IBS), and periaqueductal gray (PAG). With the aim of helping to improve the painful condition, non-pharmacological therapies have been studied, and one of them is phototherapy, a non-invasive method used by several areas of health, which has been shown to be increasingly effective in the treatment of decreased pain sensitivity. The present study aims to evaluate the effects of transcranial photobiomodulation in patients with Parkinson's disease. This is a randomized study, in which investigators will analyze the effect of FBM on pain control and on magnetic resonance images to better elucidate the connectivities of pain areas. Afterwards, the researchers will carry out a better elaboration on the treatments of individuals diagnosed with Parkinson's disease, the researchers will evaluate the pain through questionnaires, and the researchers will also evaluate the motor cognitive capacity of these patients before and after the therapy.
General:
Evaluate the effects of applying transcranial photobiomodulation in patients with Parkinson's disease who show increased pain intensity when off levodopa.
Specific:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Photobiomodulation therapy Group PBM Application of Photobiomodulation exposure time between 4 and 9 minutes, application of PBM with treatment time of 5 weeks
Radiation: Photobiomodulation
Photobiomodulation Placebo Group Appication of Photobiomodulatio off, time between 4 and 9 minutes, to 5 weeks
Radiation: Photobiomodulation
Light-Aid equipment from Bright Photomedicine-Brasil will be used, with an 850 nm Arsenide, Gallium and Aluminum (AsGaAl) LED. Exposure time between 4 and 9 minutes; radiant exposure of approximately 41mW/cm2; with 8 "clusters" in each session. Two tapes containing four "clusters" each will be arranged, and each cluster contains 25 led's adding up to a total of one hundred (100) led's arranged in each on the tape
Visual Numerical Scale
Visual Numerical Scale, a is an instrument for the qualitative assessment of pain intensity. It consists of a line numbered from zero ( 0 ) which represents total absence of pain to ten (10) which represents the worst pain the individual can feel. This scale will be applied before the first session and before the start of each transcranial phototherapy session.
Time frame: The first scale measuremente is our First day (baseline- before any procedure). All other measurement will be made each 72 hours after the beginning of the treatment with a total of 11 days.
McGuill Pain Questionnaire
Evaluate the effects of applying transcranial photobiomodulation in patients with Parkinson's disease who show increased pain intensity when off levodopa. One of the most used questionnaires for measuring pain. It allows us to identify different types of pain, being considered one of the best to assess the sensitive-discriminative, affective-motivational and cognitive dimension of pain.
Time frame: This questionaire will be aplyed before any procedure or intervention (baseline) and again after five weeks from the first procedure.
King's Parkinson's Disease Pain Scale (KPPS)
First specific scale to assess pain in individuals with Parkinson's disease. It comprises 14 items divided into 7 domains, and each item is scored by the severity of the pain multiplied by the frequency the patient feels
Time frame: This questionnaires will be applied before the treatment (baseline) and again after the end of the treatment (five weeks- from the first procedure).
Started Jun 2023 (actual). Primary completion is estimated for Oct 2023, 4 months after the start.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 4 months is below that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.